{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:16:53Z","timestamp":1775002613167,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["IIS-2019-133782"],"award-info":[{"award-number":["IIS-2019-133782"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015660","name":"UCB Pharma Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["31484"],"award-info":[{"award-number":["31484"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.yebeh.2024.109906","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T21:17:40Z","timestamp":1719436660000},"page":"109906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Efficacy and tolerability of Brivaracetam in people with intellectual disability compared to those without intellectual disability"],"prefix":"10.1016","volume":"158","author":[{"given":"Jon","family":"Allard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Henley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1419-8540","authenticated-orcid":false,"given":"Brendan","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Parrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Rajakulendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-6743","authenticated-orcid":false,"given":"Melissa","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Ellawela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-8234","authenticated-orcid":false,"given":"Phil","family":"Tittensor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjune","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Mohanraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-8499","authenticated-orcid":false,"given":"Manny","family":"Bagary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9107-5283","authenticated-orcid":false,"given":"Allan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-6933","authenticated-orcid":false,"given":"Rohit","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.109906_b0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.seizure.2015.03.016","article-title":"Prevalence of epilepsy among people with intellectual disabilities: A systematic review","volume":"29","author":"Robertson","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.109906_b0010","series-title":"People with learning disability and autistic people (LeDeR) report for 2022","author":"White","year":"2022"},{"issue":"2","key":"10.1016\/j.yebeh.2024.109906_b0015","doi-asserted-by":"crossref","first-page":"e018292","DOI":"10.1136\/bmjopen-2017-018292","article-title":"Prevalence of physical conditions and multimorbidity in a cohort of adults with intellectual disabilities with and without Down syndrome: cross-sectional study","volume":"8","author":"Kinnear","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2024.109906_b0180","unstructured":"Royal College of Psychiatrists. Management of Epilepsy in Adults with Intellectual Disability (CR203); 2017."},{"key":"10.1016\/j.yebeh.2024.109906_b0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.seizure.2018.11.001","article-title":"Awareness, attitudes, skills and training needs of psychiatrists working with adults with intellectual disability in managing epilepsy","volume":"63","author":"Lines","year":"2018","journal-title":"Seizure"},{"issue":"12","key":"10.1016\/j.yebeh.2024.109906_b0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/jnnp-2020-324660","article-title":"Epilepsy, an orphan disorder within the neurodevelopmental family","volume":"91","author":"Shankar","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.yebeh.2024.109906_b0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1192\/bja.2023.19","article-title":"Managing epilepsy in people with intellectual disabilities \u2013 creating capable communities","volume":"29","author":"Shankar","year":"2023","journal-title":"BJPsych Advances"},{"issue":"5","key":"10.1016\/j.yebeh.2024.109906_b0035","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1007\/s00415-021-10938-3","article-title":"Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study","volume":"269","author":"Sun","year":"2022","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.yebeh.2024.109906_b0040","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1007\/s00415-023-11701-6","article-title":"Mortality risk in adults with intellectual disabilities and epilepsy: an England and Wales case-control study","volume":"270","author":"Sun","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2024.109906_b0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-023-12165-4","article-title":"Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011\u20132021","author":"Shankar","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2024.109906_b0175","unstructured":"Royal College of Psychiatrists. Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability (CR206); 2017."},{"issue":"17","key":"10.1016\/j.yebeh.2024.109906_b0050","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1212\/WNL.0000000000002060","article-title":"Delivery of epilepsy care to adults with intellectual and developmental disabilities","volume":"85","author":"Devinsky","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.yebeh.2024.109906_b0055","doi-asserted-by":"crossref","first-page":"e0198261","DOI":"10.1371\/journal.pone.0198261","article-title":"Under representation of people with epilepsy and intellectual disability in research","volume":"13","author":"Shankar","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.yebeh.2024.109906_b0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1684\/epd.2021.1366","article-title":"Epilepsy in adults with neurodevelopmental disability - what every neurologist should know","volume":"24","author":"Watkins","year":"2022","journal-title":"Epileptic Disorders: Int Epilepsy J Videotape"},{"issue":"9","key":"10.1016\/j.yebeh.2024.109906_b0065","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making","volume":"26","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.yebeh.2024.109906_b0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14656566.2019.1695780","article-title":"Quality improvement in the management of people with epilepsy and intellectual disability: the development of clinical guidance","volume":"21","author":"Watkins","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2024.109906_b0075","unstructured":"EU. Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 January 2016 to 31 January 2016 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726\/2004 of the European Parliament and of the Council). Brussels; 2016."},{"issue":"3","key":"10.1016\/j.yebeh.2024.109906_b0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ane.12943","article-title":"Behavioural changes in patients with intellectual disability treated with brivaracetam","volume":"138","author":"Andres","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.yebeh.2024.109906_b0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/cjn.2019.321","article-title":"Brivaracetam: First Canadian experience in an intractable epilepsy population","volume":"47","author":"Lafortune","year":"2020","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"key":"10.1016\/j.yebeh.2024.109906_b0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yebeh.2018.11.032","article-title":"Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities","volume":"90","author":"Theochari","year":"2019","journal-title":"Epilepsy & behavior: E&B"},{"key":"10.1016\/j.yebeh.2024.109906_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106505","article-title":"Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability","volume":"99","author":"Foo","year":"2019","journal-title":"Epilepsy & Behavior: E&B"},{"issue":"4","key":"10.1016\/j.yebeh.2024.109906_b0100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"139","author":"Villanueva","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2024.109906_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106967","article-title":"Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation","volume":"106","author":"Adewusi","year":"2020","journal-title":"Epilepsy & Behavior: E&B"},{"issue":"3","key":"10.1016\/j.yebeh.2024.109906_b0110","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s13760-020-01324-3","article-title":"Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy","volume":"121","author":"Gillis","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2024.109906_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108868","article-title":"Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center","volume":"135","author":"Green","year":"2022","journal-title":"Epilepsy Behavior: E&B"},{"key":"10.1016\/j.yebeh.2024.109906_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108985","article-title":"BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam","volume":"138","author":"Naddell","year":"2023","journal-title":"Epilepsy & Behavior: E&B"},{"key":"10.1016\/j.yebeh.2024.109906_b0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.seizure.2020.02.013","article-title":"Lacosamide in the general population and in people with intellectual disability: Similar responses?","volume":"76","author":"Allard","year":"2020","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2024.109906_b0130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/ane.13368","article-title":"Eslicarbazepine acetate response in intellectual disability population versus general population","volume":"143","author":"Allard","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2024.109906_b0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.seizure.2017.05.012","article-title":"Perampanel in the general population and in people with intellectual disability: Differing responses","volume":"49","author":"Shankar","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.109906_b9000","unstructured":"World Health Organization, 2022. ICD-11: International Classification of Diseases 11th Revision. The global standard for diagnostic health information. https:\/\/icd.who.int\/en accessed on 16\/04\/2024."},{"issue":"7","key":"10.1016\/j.yebeh.2024.109906_b0140","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/epi.16068","article-title":"The medical treatment of epilepsy in the elderly: A systematic review and meta-analysis","volume":"60","author":"Lezaic","year":"2019","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2024.109906_b0145","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40266-022-00931-4","article-title":"Adjunctive brivaracetam in older patients with focal seizures: evidence from the BRIVAracetam add\u2013on First Italian netwoRk Study (BRIVAFIRST)","volume":"39","author":"Lattanzi","year":"2022","journal-title":"Drugs Aging"},{"issue":"12","key":"10.1016\/j.yebeh.2024.109906_b0150","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1111\/epi.17087","article-title":"Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up","volume":"62","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109906_b0155","first-page":"13","article-title":"Epilepsy in intellectual disabilities","volume":"13","author":"Ring","year":"2013","journal-title":"Adv Clin Neurosci Rehabilitation"},{"key":"10.1016\/j.yebeh.2024.109906_b0160","doi-asserted-by":"crossref","unstructured":"Allard J, Sellers A, Henley W, McLean B, Parrett M, Rajakulendran S, et al. Efficacy and tolerability of levetiracetam in people with and without intellectual disabilities: a naturalistic case control study, Seizure: European J Epilepsy; 2024 (in press), Doi: 10.1016\/j.seizure.2024.05.010.","DOI":"10.1016\/j.seizure.2024.05.010"},{"issue":"12","key":"10.1016\/j.yebeh.2024.109906_b0165","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1007\/s00415-023-11959-w","article-title":"Rapid switching from levetiracetam to brivaracetam in pharmaco-resistant epilepsy in people with and without intellectual disabilities: a naturalistic case control study","volume":"270","author":"Watkins","year":"2023","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.yebeh.2024.109906_b0170","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/ene.13016","article-title":"Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum","volume":"23","author":"Doran","year":"2016","journal-title":"Eur J Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024002877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024002877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T17:24:06Z","timestamp":1728235446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024002877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":37,"alternative-id":["S1525505024002877"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109906","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of Brivaracetam in people with intellectual disability compared to those without intellectual disability","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109906"}}